Oncology Central

Is in vitro-acquired resistance to enzalutamide a useful model?

0

Prostate cancer is a major health concern among men worldwide, with an estimated 234,460 new cases diagnosed and 27,350 deaths in the USA alone in 2006 [1]. Significant advancements have been achieved in the fight against this deadly disease, both in terms of secondary prevention [2] and in the management of advanced prostate cancer resistant to castration [3], namely, castration-resistant prostate cancer (CRPC).

To view restricted content, please:
Share:

Leave A Comment